Compugen

$1.49 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Compugen

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Stock Analysis

last close $1.5
1-mo return -24.6%
3-mo return -20.2%
avg daily vol. 1.13M
52-week high 7.48
52-week low 1.38
market cap. $130M
forward pe -
annual div. -
roe -33.3%
ltg forecast -
dividend yield -
annual rev. $19M
inst own. 39%
baraka

Subscribe now for daily local and international financial news

Subscribe